Nuvaring competition, page-2

First 2 Last

Share
Profile

Follow
Patrick31

1,527 Posts.

269

28/11/19

19:01

Post #: 41693197
Share

Originally posted by jamarco: ↑

Just had a quick read through the latest updates from competitors re delays and potential launch timing:

DR REDDY - received complete response letter from FDA (same as Mayne) in July/August this year (announced in August). No ETA for launch, but based on Mayne receiving this letter Dec 2019 you would expect we are approx. 6 months ahead.

AMNEAL - advised market in July this year that they would be delayed. No ETA and can not find any details as to why the delay.

TEVA - announced in their 3Q results TC last month that launch is pushed to 2020, no further clarification or details.

So at this point, you would have to assume that if there is no problem with the re-submission and we get approved, we will either be first or a close second (behind Teva) to market. This is positive.

In terms of net sales. Current Nuvaring market in USD is just shy of $1B, so equivalent to AUD $1.4B. As a whole I believe generic conversion in the US is around 90%, though it takes some time from a new launch to get there and also takes multiple competitors. Let's say we launch at the same time as TEVA and collectively capture 40% market share in year 1 (20% each) at a discount of 50%, then this is equivalent to net sales of AUD $140M. I have no idea what generic discounting in the US looks like and would assume with only two players initially they would be smart and keep in much lower than 50%, but again, not sure.

Thoughts?

Expand

I only posted a few days ago.
Mithra on 6/ Nov gained approval for
Myring / Nuvaring Equivalent Shelf Life
Extension from 18- 24 months.
Also The Storage Temp does not have
to be Refrigerated 2-8*c.
All Things Being Equal ( other than those
2 benefits) Which One Would You Buy ???

MYX Price at posting: 44.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

WCE

West Coast Silver flags capital raise as Falcon hits potential gold target

STX

Carnarvon becomes Strike's largest holder; market not happy

PSC

Prospect's Mumbezhi Project puts it at the middle of copper's megatrend. And FQM just bought in

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

PTX

This rare type of lymphoma ruins the body – so do existing treatments. Prescient could have a solution

First 2 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $5.17		Change 0.010(0.19%)		Mkt cap ! $416.7M

Open	High	Low	Value	Volume
$5.17	$5.19	$5.12	$193.4K	37.47K

Buyers (Bids)

No.	Vol.	Price($)
9	4519	$5.15

Sellers (Offers)

Price($)	Vol.	No.
$5.18	802	4

View Market Depth

No.	Vol.	Price($)
4	3543	5.140
4	10144	5.130
2	370	5.120
1	100	5.110
3	1540	5.100

Price($)	Vol.	No.
5.170	808	5
5.180	1092	4
5.190	3830	6
5.200	21015	4
5.210	1028	3

Last trade - 11.09am 22/07/2025 (20 minute delay)

MYX (ASX) Chart

Nuvaring competition, page-2

West Coast Silver flags capital raise as Falcon hits potential gold target

Carnarvon becomes Strike's largest holder; market not happy

Prospect's Mumbezhi Project puts it at the middle of copper's megatrend. And FQM just bought in

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

This rare type of lymphoma ruins the body – so do existing treatments. Prescient could have a solution

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Nuvaring competition, page-2

Top Stories

West Coast Silver flags capital raise as Falcon hits potential gold target

Carnarvon becomes Strike's largest holder; market not happy

Prospect's Mumbezhi Project puts it at the middle of copper's megatrend. And FQM just bought in

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

This rare type of lymphoma ruins the body – so do existing treatments. Prescient could have a solution

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News